EULAV Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

EULAV Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-34,237	Closed	-$1.57M	–	293
2016 Q3	$1.57M	Hold	34,237	–	–	0.08%	218
2016 Q2	$1.72M	Hold	34,237	–	–	0.09%	214
2016 Q1	$1.83M	Hold	34,237	–	–	0.1%	216
2015 Q4	$2.25M	Sell	34,237 -9,000	-21%	-$556K	0.12%	206
2015 Q3	$2.44M	Sell	43,237 -1,000	-2%	-$64.8K	0.14%	201
2015 Q2	$2.61M	Hold	44,237	–	–	0.14%	215
2015 Q1	$2.76M	Sell	44,237 -36,000	-45%	-$2.09M	0.14%	211
2014 Q4	$4.61M	Sell	80,237 -10,000	-11%	-$557K	0.25%	144
2014 Q3	$4.85M	Buy	90,237 +7,000	+8%	+$371K	0.26%	142
2014 Q2	$4.36M	Hold	83,237	–	–	0.23%	148
2014 Q1	$4.4M	Sell	83,237 -8,000	-9%	-$370K	0.24%	152
2013 Q4	$3.66M	Sell	91,237 -12,500	-12%	-$492K	0.2%	169
2013 Q3	$3.92M	Sell	103,737 -12,700	-11%	-$495K	0.23%	157
2013 Q2	$4.56M	Buy	+116,437	New	+$4.53M	0.28%	128

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

EULAV Asset Management's TEVA Position: Q4 2016 in Review

EULAV Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 34,237 shares — an estimated $1.57M sold.

EULAV Asset Management first reported a position in TEVA in Q2 2013 and held it in 14 quarters. The position peaked at $4.85M in Q3 2014. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

EULAV Asset Management reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
EULAV Asset Management sold 34,237 Teva Pharmaceuticals shares in Q4 2016, an estimated $1.57M.
EULAV Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 14 quarters.
EULAV Asset Management's Teva Pharmaceuticals position peaked at $4.85M in Q3 2014.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on EULAV Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.